GGrantIndex
Sort

89,613 grants matching depression

Alcohol Pharmacokinetics and Pharmacodynamics in Humans

$3,037,867
Vijay Arjun Ramchandani · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2016 · AA

Women HIV Cohort Study: HIV infection and treatment among women of reproductive age

$3,035,518
Maria Luisa Alcaide · University Of Miami School Of Medicine · R01 · FY2020 · HD

PHARMACOGENETICS OF MEMBRANE TRANSPORTERS

$3,034,266
University Of California San Francisco · U01 · FY2001 · GM

MIND DIET AND DEMENTIA PREVENTION IN ISCHEMIC STROKE PATIENTS

$3,033,308
Neelum T Aggarwal · Rush University Medical Center · R01 · FY2024 · AG

A novel and highly selective orexin 1 receptor antagonist for the treatment of patients with opioid use disorder.

$3,032,676
Fiona J. Thomson · Astrazeneca Pharmaceuticals, Lp · UG3 · FY2021 · DA

Early Markers of Alzheimer Disease

$3,029,330
Susan Resnick · National Institute On Aging · ZIA · FY2019 · AG

PPD, PREVENTING POSTPARTUM DEPRESSION - A REAL-WORLD EXAMINATION OF A PREDICTIVE TEST FOR PPD

$3,028,589
Dionysus Digital Health Inc · · FY2025 · Defense Health Agency

A novel and highly selective orexin 1 receptor antagonist for the treatment of patients with opioid use disorder

$3,027,897
Paul J Kenny · Eolas Therapeutics, Inc. · UH3 · FY2025 · DA

International Epidemiologic Databases to Evaluate AIDS - Southern Africa (IeDEA-SA)

$3,025,969
Matthias Egger · Universitat Bern · U01 · FY2017 · AI

A novel and highly selective orexin 1 receptor antagonist for the treatment of patients with opioid use disorder.

$3,024,162
Ian Gurrell · Astrazeneca Pharmaceuticals, Lp · UH3 · FY2024 · DA

Fragmented early-life experiences, aberrant circuit maturation, emotional vulnerabilities

$3,020,227
Tallie Z. Z Baram · University Of California-Irvine · P50 · FY2019 · MH

Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect

$3,019,176
Carlos Zarate · National Institute Of Mental Health · ZIA · FY2020 · MH

Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders

$3,019,176
Carlos Zarate · National Institute Of Mental Health · ZIA · FY2020 · MH

Risk and Resilience, Clinical presentation, and Biomarker Profiles of Chronic Traumatic Encephalopathy and Related Dementias: The DIAGNOSE CTE Research Project II

$3,019,032
Michael Alosco · Boston University Medical Campus · R01 · FY2025 · NS

Impact of Timing, Targeting, and Brain State on rTMS of Human and Non-Human Primates

$3,016,179
Marc A Sommer · Duke University · RF1 · FY2017 · MH

Cellular And Synaptic Physiology Of Hippocampal Interneurons

$3,011,240
Chris J McBain · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2024 · HD

Mechanisms Of Synaptic Plasticity In The Adult And Developing Nervous System

$3,008,772
Serena M Dudek · National Institute Of Environmental Health Sciences · ZIA · FY2016 · ES

Small blood pumps for small patients

$3,007,461
Trevor Arnoult Snyder · Vadovations, Inc. · R44 · FY2017 · HL

IGF::OT::IGF Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of Ke

$3,005,599
X X · Massachusetts General Hospital · N02 · FY2013 · DA

Functional genetic analyses of existing data resources to expand AD gene discovery

$3,002,657
Jennifer Below · Vanderbilt University Medical Center · RF1 · FY2019 · AG

PRIDEnet for the All of Us Research Program

$3,001,929
Mitchell Ryan Lunn · Stanford University · OT2 · FY2023 · OD

International Epidemiologic Databases to Evaluate AIDS - Southern Africa (IeDEA-SA)

$3,000,683
Matthias Egger · Universitat Bern · U01 · FY2019 · AI

NIMH Center for Collaborative Genetic Studies

$3,000,000
Jay Arnold Tischfield · Rutgers, The State Univ Of N.J. · U24 · FY2008 · MH

Health Outcomes around Pregnancy and Exposure to HIV/ARV (HOPE): Extending the Reach of PHACS to Examine Women's Health

$3,000,000
Paige L Williams · Harvard School Of Public Health · R01 · FY2020 · HD

NICHD RADX TECH ACT ENDO CHALLENGE AWARD - INITIAL OBLIGATION

$3,000,000
· N01 · FY2024 · HD